Hyderabad: Bharat Biotech announced today safety and efficacy analysis data from Phase III clinical trials of COVAXIN, a whole virion inactivated vaccine against SARS-CoV2, was developed in partnership with ICMR and NIV Pune.
The company claimed that the vaccine has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial.
Covaxin demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%.
“In the Phase 3 trial conducted by Bharat Biotech, subjects vaccinated with Covaxin achieved greater protection against emerging B.1.617.2 (delta) and B.1.351 (beta) variants than those who had previous natural infections. Results showed an efficacy rate of 65.2%”, a statement said.
Phase 3 clinical trials of COVAXIN was an event driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India.